Firma TolerogenixX, Autor bei PR-Web

TolerogenixX Receives Approval to Start Phase IIb Trial for its Immune Tolerance-Inducing MIC-Lx Cell Therapy

Posted on 28. March 202228. March 2022 by Firma TolerogenixX Posted in General Tagged biopsy, cell, cells, centric, ckd, clinical, graft, hla, lupus, patients, production, therapy, tolerogenixx, transplant, with

Multi-centric clinical study in patients with stage 5 chronic kidney disease (CKD) receiving a living donor kidney Study of MIC-Lx cell treatment, a potentially curative approach to achieve sustained immune tolerance in transplanted and autoimmune patients as shown in […]

TolerogenixX Reports Positive Phase Ib Data of its Lead Product to Combat Transplant Rejection

Posted on 11. May 20207. April 2021 by Firma TolerogenixX Posted in General Tagged cell, cells, clinical, endpoint, graft, hla, kidney, lupus, mics, patients, sam, therapy, transplant, varicella, with

. – Product shows excellent safety and tolerability – Enables long-term reduction of standard medications and side effects while maintaining immune tolerance and transplant function – Findings endorsed by third-party experts TolerogenixX GmbH, a biopharmaceutical company developing personalized, cellular therapies […]